Compare Stocks → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:GDRX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGDRXGoodRx$7.87+4.1%$7.05$4.14▼$9.37$2.95B1.371.76 million shs1.12 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGDRXGoodRx0.00%+10.22%+12.27%-5.75%+44.94%The Only Energy Play You Should Be Looking At (Ad)Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGDRXGoodRx2.5 of 5 stars3.30.00.00.02.41.71.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGDRXGoodRx2.55Moderate Buy$9.1115.70% UpsideCurrent Analyst RatingsLatest GDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2024GDRXGoodRxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$8.00 ➝ $10.005/20/2024GDRXGoodRxBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$9.00 ➝ $10.005/16/2024GDRXGoodRxTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $16.005/16/2024GDRXGoodRxRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/10/2024GDRXGoodRxKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Weight ➝ Overweight$9.003/25/2024GDRXGoodRxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.00(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGDRXGoodRx$750.27M3.94$0.41 per share19.06$1.68 per share4.68Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGDRXGoodRx-$8.87M-$0.01N/A31.483.67-0.86%3.45%1.70%8/14/2024 (Estimated)Latest GDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024GDRXGoodRx$0.04$0.03-$0.01$0.06$196.20 million$197.88 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGDRXGoodRxN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGDRXGoodRx1.026.296.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGDRXGoodRx63.77%Insider OwnershipCompanyInsider OwnershipGDRXGoodRx4.17%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGDRXGoodRx694375.20 million359.56 millionOptionableGDRX HeadlinesRecent News About These CompaniesJune 1 at 7:01 PM | accesswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 21, 2024 in GoodRx Lawsuit - GDRXJune 1 at 12:00 PM | accesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXMay 31 at 12:00 PM | accesswire.comGoodRx Holdings, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRXMay 31 at 11:00 AM | accesswire.comDEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 31 at 10:40 AM | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxMay 30 at 4:05 PM | businesswire.comSimon Patterson Joins GoodRx Board of DirectorsMay 30 at 3:15 PM | accesswire.comClass Action Filed Against GoodRx Holdings, Inc. (GDRX) - June 21, 2024 Deadline to Join - Contact Levi & KorsinskyMay 30 at 2:51 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXMay 30 at 2:15 PM | accesswire.comGoodRx Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRXMay 30 at 2:00 PM | accesswire.comInvestors who Lost Money on GoodRx Holdings, Inc.(GDRX) Should Contact Levi & Korsinsky About Pending Class Action - GDRXMay 30 at 8:35 AM | businesswire.comGoodRx Named One of the 2024 TIME100 Most Influential CompaniesMay 30 at 6:45 AM | prnewswire.comLevi & Korsinsky Reminds GoodRx Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 - GDRXMay 30 at 6:01 AM | marketbeat.comTrexquant Investment LP Increases Stock Position in GoodRx Holdings, Inc. (NASDAQ:GDRX)May 29, 2024 | prnewswire.comShareholders that lost money on GoodRx Holdings, Inc.(GDRX) should contact The Gross Law Firm about pending Class Action - GDRXMay 29, 2024 | markets.businessinsider.comIMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmMay 28, 2024 | bovnews.comGoodRx Holdings Inc (NASDAQ:GDRX) Stock is trading Above 2.60% From 50-Day SMAMay 28, 2024 | prnewswire.comROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXMay 28, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitMay 28, 2024 | seekingalpha.comGoodRx: Encouraging Profit Stabilization (Rating Upgrade)May 27, 2024 | markets.businessinsider.comGoodRx Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - GDRXMay 27, 2024 | stockhouse.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGoodRxNASDAQ:GDRXGoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
